Prostate Cancer - Results from #1660

Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era. March 18, 2024

Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer. March 18, 2024

Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07). March 18, 2024

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. March 18, 2024

Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer. March 18, 2024

ProtecT trial: What's new after 15 years of follow-up: Re: Hamdy FC and colleagues; N Engl J Med. 2023 Apr 27. March 15, 2024

Robot-assisted vs open retropubic radical prostatectomy: a propensity score-matched comparative analysis based on 15 years and 18,805 patients. March 15, 2024

Demographic and Clinical Factors Associated With Health-Related Quality-of-Life Profiles Among Prostate Cancer Survivors. March 15, 2024

Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE). March 15, 2024

Cancer centers of excellence for the multidisciplinary management of urologic cancers: The intersection between education, research, and healthcare. March 15, 2024

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. March 15, 2024

Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors. March 14, 2024

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer. March 14, 2024

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. March 14, 2024

Identifying low cancer-specific mortality risk lymph node-positive radical prostatectomy patients. March 14, 2024

A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities. March 14, 2024

A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. March 14, 2024

Influence of early apical release on outcomes in endoscopic enucleation of the prostate: results from a multicenter series of 4392 patients. March 13, 2024

Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). March 13, 2024

Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk. March 13, 2024

Page 84 of 1458